Clinical Trial Update: A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating talquetamab in people with multiple myeloma who have previously received BCMA CAR T-cell therapy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Talquetamab (talquetamab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING